Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 11/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.38 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.38 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18927171 | 0.94 | P2RY12 (0.39) | P2RY12PRMT6ADORA1DNPH1P2RY2 | |
| SCHEMBL18917301 | 0.94 | P2RY12 (0.39) | P2RY12PRMT6ADORA1DNPH1P2RY2 | |
| SCHEMBL18937379 | 0.94 | P2RY12 (0.42) | P2RY12PRMT6ADORA1DNPH1P2RY2 | |
| SCHEMBL31430106 | 0.93 | P2RY12 (0.43) | P2RY12PRMT6ADORA1DNPH1 | |
| SCHEMBL23624675 | 0.90 | P2RY12 (0.47) | P2RY12ADORA1DNPH1P2RY2P2RY1 | |
| SCHEMBL31430083 | 0.90 | P2RY12 (0.39) | P2RY12PRMT6DNPH1P2RY2P2RY1 | |
| SCHEMBL24322108 | 0.88 | P2RY12 (0.38) | P2RY12PRMT6ADORA1DNPH1P2RY2 | |
| SCHEMBL19762770 | 0.88 | P2RY12 (0.41) | P2RY12PRMT6ADORA1DNPH1P2RY2 | |
| SCHEMBL19250016 | 0.88 | P2RY12 (0.44) | P2RY12DNPH1P2RY2P2RY1P2RY6 | |
| SCHEMBL22879142 | 0.88 | P2RY12 (0.36) | P2RY12PRMT6ADORA1DNPH1P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233430-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233430-A1 | Novel Compounds | STING1, IRF3, IFNAR1 | P2RY12 86/4885PRMT6 2225/4885ADORA1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.